Nise Hitomi Yamaguchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Nise Hitomi Yamaguchi has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
Fernanda R. Tavares
2 shared publicationsPaulo H. Aguiar
2 shared publicationsA A Laudanna
Department of Gastroenterology, Medical School, University of São Paulo
1 shared publicationA S Duarte
1 shared publicationAbel Garcia
1 shared publicationAlecsander P. da Silva
Department of Pathology, School of Medicine, University of São Paulo and
1 shared publication
Latest Publications
- Open Access
- 1 May 2019
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 8 (S1) , S3-S6
Smoking, immunity, and DNA damage
Smoking, immunity, and DNA damage
- 1 May 2019
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 8 (S1) , S3-S6
Open AccessSmoking, immunity, and DNA damage
Smoking, immunity, and DNA damage
- 1 January 2017
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 12 (1) , S56-S57
ED12.06 Tobacco Control Policies in Latin America
- 1 January 2017
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 12 (1) , S56-S57
ED12.06 Tobacco Control Policies in Latin America
- Open Access
- 3 December 2015
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 9
WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results?
In recent years, with the rise of immunotherapeutic agents for cancer treatment, we have observed a paradigm shift in oncology drug development. One common problem accompanying such paradigm shifts is how to build research strategies to fit the mechanism of action of the newer compounds. Developing immunotherapy in oncology requires us to address the unique characteristics of immunotherapeutic agents and to provide adequate tools for their evaluation, including the adjustment of clinical trial endpoints. Immunotherapy creates patterns of response different from those of chemotherapy, and thus they are not captured by the traditional World Health Organisation (WHO) tumour response criteria or the RECIST. Revisiting the results of pembrolizumab in patients with melanoma can help to evaluate the efficacy of the immune-related response criteria (irRC) as the gold standard for evaluating the clinical response of immunologic agents in oncology.
- 3 December 2015
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 9
Open AccessWHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results?
In recent years, with the rise of immunotherapeutic agents for cancer treatment, we have observed a paradigm shift in oncology drug development. One common problem accompanying such paradigm shifts is how to build research strategies to fit the mechanism of action of the newer compounds. Developing immunotherapy in oncology requires us to address the unique characteristics of immunotherapeutic agents and to provide adequate tools for their evaluation, including the adjustment of clinical trial endpoints. Immunotherapy creates patterns of response different from those of chemotherapy, and thus they are not captured by the traditional World Health Organisation (WHO) tumour response criteria or the RECIST. Revisiting the results of pembrolizumab in patients with melanoma can help to evaluate the efficacy of the immune-related response criteria (irRC) as the gold standard for evaluating the clinical response of immunologic agents in oncology.
- 1 July 2015
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 39 (2) , 299-303
Percutaneous CT-Guided Cryoablation as an Alternative Treatment for an Extensive Pelvic Bone Giant Cell Tumor
- 1 July 2015
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 39 (2) , 299-303
Percutaneous CT-Guided Cryoablation as an Alternative Treatment for an Extensive Pelvic Bone Giant Cell Tumor
- Open Access
- 1 April 2014
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 9 (4) , 438-441
E-Cigarettes and Cancer Patients
- 1 April 2014
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 9 (4) , 438-441
Open AccessE-Cigarettes and Cancer Patients
- Open Access
- 1 February 2014
- Vol. 5 (1) , 57-66-66
Gefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study
Gefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study
- 1 February 2014
- Vol. 5 (1) , 57-66-66
Open AccessGefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study
Gefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study
- Open Access
- 9 December 2013
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 19 (1) , 61-67
Barriers and Challenges to Global Clinical Cancer Research
Background.: There are concerns about growing barriers to cancer research. We explored the characteristics of and barriers to global clinical cancer research. Methods.: The American Society of Clinical Oncology International Affairs Committee invited 300 selected oncologists with research experience from 25 countries to complete a Web-based survey. Fisher's exact test was used to compare answers between participants from high-income countries (HICs) and low- and middle-income countries (LMICs). Barriers to clinical cancer research were ranked from 1 (most important) to 8 (least important). Mann-Whitney's nonparametric test was used to compare the ranks describing the importance of investigated obstacles. Results.: Eighty oncologists responded, 41 from HICs and 39 from LMICs. Most responders were medical oncologists (62%) at academic hospitals (90%). Researchers from HICs were more involved with academic and industry-driven research than were researchers from LMICs. Significantly higher proportions of those who considered their ability to conduct academic research and industry-driven research over the past 5 years more difficult were from HICs (73% vs. 27% and 70% vs. 30%, respectively). Concerning academic clinical cancer research, a lack of funding was ranked the most important (score: 3.16) barrier, without significant differences observed between HICs and LMICs. Lack of time or competing priorities and procedures from competent authorities were the second most important barriers to conducting academic clinical research in HICs and LMICs, respectively. Conclusion.: Lack of funding, lack of time and competing priorities, and procedures from competent authorities might be the main global barriers to academic clinical cancer research.
- 9 December 2013
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 19 (1) , 61-67
Open AccessBarriers and Challenges to Global Clinical Cancer Research
Background.: There are concerns about growing barriers to cancer research. We explored the characteristics of and barriers to global clinical cancer research. Methods.: The American Society of Clinical Oncology International Affairs Committee invited 300 selected oncologists with research experience from 25 countries to complete a Web-based survey. Fisher's exact test was used to compare answers between participants from high-income countries (HICs) and low- and middle-income countries (LMICs). Barriers to clinical cancer research were ranked from 1 (most important) to 8 (least important). Mann-Whitney's nonparametric test was used to compare the ranks describing the importance of investigated obstacles. Results.: Eighty oncologists responded, 41 from HICs and 39 from LMICs. Most responders were medical oncologists (62%) at academic hospitals (90%). Researchers from HICs were more involved with academic and industry-driven research than were researchers from LMICs. Significantly higher proportions of those who considered their ability to conduct academic research and industry-driven research over the past 5 years more difficult were from HICs (73% vs. 27% and 70% vs. 30%, respectively). Concerning academic clinical cancer research, a lack of funding was ranked the most important (score: 3.16) barrier, without significant differences observed between HICs and LMICs. Lack of time or competing priorities and procedures from competent authorities were the second most important barriers to conducting academic clinical research in HICs and LMICs, respectively. Conclusion.: Lack of funding, lack of time and competing priorities, and procedures from competent authorities might be the main global barriers to academic clinical cancer research.
- 1 October 2011
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 11 (10) , 1343-1345
Treatment advances for glioblastoma
- 1 October 2011
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 11 (10) , 1343-1345
Treatment advances for glioblastoma
- 1 January 2008
- Vol. 29 (4) , 313-20
Genetic polymorphisms, the metabolism of estrogens and breast cancer: a review.
Breast cancer is the most common female cancer and the second cause of cancer death in women. Despite recent breakthroughs, much of the etiology of this disease is unknown and the most important risk factor, i.e., exposure to endogenous and exogenous estrogen throughout life cannot explain the heterogeneity of prognosis nor clinical features of patients. Recently, many gene polymorphisms in the metabolism of breast cancer have been described as possible neoplasm etiologic factors. This review is an attempt to summarize the current knowledge about these polymorphisms and to determine new target genes for diagnosis and treatment of the disease. Polymorphisms in the genes CYP17, CYP19, CYP1A1, CYP1A2, CYP1B1, UGT1A1, SULT1A1, 17-hydroxysteroid-dehydrogenase, COMT, GST, ESR1, and ESR2 are described.
- 1 January 2008
- Vol. 29 (4) , 313-20
Genetic polymorphisms, the metabolism of estrogens and breast cancer: a review.
Breast cancer is the most common female cancer and the second cause of cancer death in women. Despite recent breakthroughs, much of the etiology of this disease is unknown and the most important risk factor, i.e., exposure to endogenous and exogenous estrogen throughout life cannot explain the heterogeneity of prognosis nor clinical features of patients. Recently, many gene polymorphisms in the metabolism of breast cancer have been described as possible neoplasm etiologic factors. This review is an attempt to summarize the current knowledge about these polymorphisms and to determine new target genes for diagnosis and treatment of the disease. Polymorphisms in the genes CYP17, CYP19, CYP1A1, CYP1A2, CYP1B1, UGT1A1, SULT1A1, 17-hydroxysteroid-dehydrogenase, COMT, GST, ESR1, and ESR2 are described.
- 30 June 2004
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 77 (6) , 1883-1890
Neuroendocrine and biologic features of primary tumors and tissue in pulmonary large cell carcinomas
- 30 June 2004
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 77 (6) , 1883-1890
Neuroendocrine and biologic features of primary tumors and tissue in pulmonary large cell carcinomas